Maygace Altas Dosis (Megestrol Acetate)

Megestrol acetate is a synthetic progestin that binds to progesterone receptors, altering gene expression that suppresses tumor growth in hormone‑responsive cancers. Receptor activation also influences hypothalamic pathways, increasing appetite and promoting weight gain, which is beneficial in cachectic patients.

The appropriate dose of Maygace Altas Dosis is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosage may vary for appetite stimulation versus oncologic indications, and adjustments are made according to clinical judgment.

Safety of megestrol acetate in pregnancy and lactation has not been established. Because it is a hormonal agent, it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, and it should be used only under specialist supervision.

To order Maygace Altas Dosis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Megestrol acetate is often compared with medroxyprogesterone acetate, another synthetic progestin. Both agents stimulate appetite, but megestrol acetate typically shows a stronger effect on weight gain and has additional antineoplastic activity, whereas medroxyprogesterone may have a more favorable side‑effect profile for some patients.

Store Maygace Altas Dosis at room temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Maygace Altas Dosis is taken orally. The tablet should be swallowed whole with a glass of water, preferably with food to reduce gastrointestinal discomfort, unless the prescriber provides alternative instructions.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal insufficiency due to cortisol suppression, and severe hyperglycemia that may precipitate diabetic complications. Patients should be monitored closely for signs of these conditions.

Maygace Altas Dosis should be avoided in individuals with known hypersensitivity to megestrol acetate, active thromboembolic disease, uncontrolled diabetes, or in pregnant women unless absolutely necessary. Clinicians should also exercise caution in patients with severe hepatic impairment.